About
Nihal is a Partner at F-Prime Capital based in the London office and focuses primarily on biotech and healthcare IT in Europe. At F-Prime Nihal has been involved in a number of cell and gene therapy investments including as a member of the founding team of Orchard Therapeutics. Prior to joining F-Prime in 2013, he worked as a strategy consultant at BCG and as an academic physician at Oxford University and UCL Hospitals.
Nihal holds a MB BChir with distinction from the University of Cambridge and is a Member of the Royal College of Physicians.
-
Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and hematological cancers. Learn more at www.adaptimmune.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Oxford, UK
-
Year Invested
2014
-
Team
-
-
Affinia Therapeutics is a gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies and a mission to develop transformative medicines for devastating diseases. Learn more at www.affiniatx.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Waltham, MA
-
Year Invested
2019
-
Team
-
-
AviadoBio is a pioneering gene therapy company focused on developing and delivering transformative medicines for people living with neurodegenerative disorders. Learn more at www.aviadobio.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
London, UK and New Jersey, US
-
Year Invested
2020
-
Team
-
-
Buoy is an online symptom and cure checker that uses an intelligent algorithm backed by medical data to diagnose patients. Learn more at www.buoyhealth.com.
-
Category
- Health IT/Services
-
Status
- Private
-
Location
Boston, MA
-
Year Invested
2017
-
Team
-
-
Caribou (NASDAQ:CRBU) is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies. Learn more at www.cariboubio.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Berkeley, CA
-
Year Invested
2015
-
Team
-
-
Cipla Health focuses on developing and commercializing products in the consumer healthcare and over-the-counter categories. Learn more at www.ciplahealth.in.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Mumbai, India
-
Year Invested
2016
-
Team
-
-
CORE provides high-end diagnostics services for disease stratification and therapy selection. Learn more at www.corediagnostics.in.
-
Category
- MedTech
-
Status
- Private
-
Location
Gurgaon, Haryana, India
-
Year Invested
2016
-
Team
-
-
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g. chemotherapy). Learn more at www.ensoma.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Boston, MA
-
Year Invested
2021
-
Team
-
-
Indalo Therapeutics, a preclinical biotechnology company dedicated to developing therapies for fibrosis, is formed with an experienced team, strong IP, and robust portfolio of drug candidates. Learn more at www.indalotherapeutics.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
St. Louis, MO
-
Year Invested
2017
-
Team
-
-
Leyden Labs platform targets commonalities of viral families to protect humanity from known and future viruses. Learn more at www.leydenlabs.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Amsterdam, The Netherlands and Boston, MA
-
Year Invested
2021
-
Team
-
-
Orchard Therapeutics (NASDAQ:ORTX) Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Learn more at www.orchard-tx.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
London, United Kingdom
-
Year Invested
2016
-
Team
-
-
Oviva is a new type of healthcare provider using technology to scale the dietitian workforce to help meet the growing number of patients with diet-related health conditions. Learn more at www.oviva.com/uk/.
-
Category
- Health IT/Services
-
Status
- Private
-
Location
Zurich, Switzerland
-
Year Invested
2016
-
Team
-
-
Proximie is a technology platform that uses a combination of machine learning, artificial intelligence and augmented reality to allow clinicians to virtually ‘scrub in’ and collaborate with each other from anywhere in the world. Learn more at proximie.com.
-
Category
- Health IT/Services
-
Status
- Private
-
Location
London, United Kingdom
-
Year Invested
2021
-
Team
-
-
Sana Biotechnology, Inc. (NASDAQ:SANA) is focused on creating and delivering engineered cells as medicine for patients. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and changes how we approach treating disease. Learn more about Sana at www.sana.com.
-
Category
- Therapeutics
-
Status
- Public
-
Location
Cambridge, MA
-
Year Invested
2018
-
Team
-
-
Turnstone Biologics is transforming patient care with a new class of targeted viral immunotherapies to fight cancer. Learn more at www.turnstonebio.com.
-
Category
- Therapeutics
-
Status
- Private
-
Location
Ottawa, Canada
-
Year Invested
2016
-
Team
-
